Discussion
AML, infections, myelosuppression
INFECTIONS, AML
This multicenter, phase 2 single-arm study provides the first evidence that VAH regimen has a robust CRc and encouraging OS in patients with R/R AML. Furthermore, VAH regimen is a well-tolerated regimen.Reported CRc rates of venetoclax-based treatments for R/R AML varied greatly, ranging from 20 to 67% [The collaboration mechanism of homoharringtonine and venetoclax in anti-leukemia effect has been recently demonstrated [Some studies including our own report suggested that the sensitivity to venetoclax-based therapy was related with molecular mutations of AML [One of the main concerns when combining triplet agents was the potential for increased side-effect profile, especially myelosuppression and infections. The venetoclax was administered on D1-28 in the venetoclax-based two-drug combination regimen for R/R AML [Our study has some limitations. It is a single-arm trial that limit the conclusions. Although our median follow-up is more than a year, longer follow-up is needed to confirm the durability of the responses and long-term survival.